热门出版物 - 学术资源搜索

h5 指数:57
h5 中位数:89

h5 指数是指在过去整整 5 年中所发表文章的 h 指数。h 指在 2018-2022 年间发表的 h 篇文章每篇至少都被引用过 h 次的最大值。隐藏

出版物的 h5 中位数，是指出版物的 h5 指数所涵盖的所有文章获得的引用次数的中位值。隐藏

#3 AIDS & HIV

标题/作者	引用次数	年份
Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015 H Wang, TM Wolock, A Carter, G Nguyen, HH Kyu, E Gakidou, SI Hay, ... The Lancet HIV 3 (8), e361-e387	474	2016
Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies A Trickey, MT May, JJ Vehreschild, N Obel, MJ Gill, HM Crane, ... The Lancet HIV 4 (8), e349-e356	409	2017
Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial JK Rockstroh, M Nelson, C Katlama, J Lalezari, J Mallolas, M Bloch, ... The Lancet HIV 2 (8), e319-e327	295	2015
Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study JM Molina, I Charreau, B Spire, L Cotte, J Chas, C Capitant, C Tremblay, ... The Lancet HIV 4 (9), e402-e410	169	2017
Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial J Lo, MT Lu, EJ Ihenachor, J Wei, SE Looby, KV Fitch, J Oh, ... The Lancet HIV 2 (2), e52-e63	167	2015
Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis N Ford, Z Shubber, G Meintjes, B Grinsztejn, S Eholie, EJ Mills, ... The Lancet HIV 2 (10), e438-e444	162	2015
Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study JM Molina, B Clotet, J van Lunzen, A Lazzarin, M Cavassini, K Henry, ... The Lancet HIV 2 (4), e127-e136	154	2015
Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a community-wide phylogenetic study T de Oliveira, ABM Kharsany, T Gräf, C Cawood, D Khanyile, A Grobler, ... The Lancet HIV 4 (1), e41-e50	152	2017
HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial MB Deutsch, DV Glidden, J Sevelius, J Keatley, V McMahan, J Guanira, ... The Lancet HIV 2 (12), e512-e519	150	2015
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study C Mussini, P Lorenzini, A Cozzi-Lepri, G Lapadula, G Marchetti, E Nicastri, ... The Lancet HIV 2 (3), e98-e106	147	2015
Botswana's progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based survey T Gaolathe, KE Wirth, MP Holme, J Makhema, S Moyo, U Chakalisa, ... The Lancet HIV 3 (5), e221-e230	139	2016
Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study RU Hernández-Ramírez, MS Shiels, R Dubrow, EA Engels The Lancet HIV 4 (11), e495-e504	139	2017
Retention in care during the first 3 years of antiretroviral therapy for women in Malawi's option B+ programme: an observational cohort study AD Haas, L Tenthani, MT Msukwa, K Tal, A Jahn, OJ Gadabu, A Spoerri, ... The Lancet HIV 3 (4), e175-e182	135	2016
Time trends for risk of severe age-related diseases in individuals with and without HIV infection in Denmark: a nationwide population-based cohort study LD Rasmussen, MT May, G Kronborg, CS Larsen, C Pedersen, J Gerstoft, ... The Lancet HIV 2 (7), e288-e298	134	2015
Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study BR Bavinton, AN Pinto, N Phanuphak, B Grinsztejn, GP Prestage, ... The Lancet HIV 5 (8), e438-e447	134	2018
Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study JH Elliott, JH McMahon, CC Chang, SA Lee, W Hartogensis, N Bumpus, ... The Lancet HIV 2 (12), e520-e529	134	2015
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial JE Gallant, ES Daar, F Raffi, C Brinson, P Ruane, E DeJesus, M Johnson, ... The Lancet HIV 3 (4), e158-e165	124	2016
Promoting male partner HIV testing and safer sexual decision making through secondary distribution of self-tests by HIV-negative female sex workers and women receiving antenatal and post-partum care in Kenya: a cohort study H Thirumurthy, SH Masters, SN Mavedzenge, S Maman, E Omanga, ... The Lancet HIV 3 (6), e266-e274	117	2016
Interventions to improve adherence to antiretroviral therapy: a systematic review and network meta-analysis S Kanters, JJH Park, K Chan, ME Socias, N Ford, JI Forrest, K Thorlund, ... The Lancet HIV 4 (1), e31-e40	116	2017
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study A Mocroft, JD Lundgren, M Ross, CA Fux, P Reiss, O Moranne, P Morlat, ... The Lancet HIV 3 (1), e23-e32	113	2016

1 - 20

计算机程序会自动估算并确定日期和引用次数。